[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"peripheral-pulmonary-lesion\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:peripheral-pulmonary-lesion":24},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,40],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":25,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100593323","diagnostic-value-of-confocal-laser-endomicroscopy-celtouch-for-peripheral-lung-lesions-100593323",false,"NCT07004946","Diagnostic Value of Confocal Laser Endomicroscopy (CelTouch) for Peripheral Lung Lesions","Inclusion Criteria:\n\n1. Aged ≥18 years, with lung lesions detected by chest CT and scheduled for lung biopsy;\n2. Preoperative CT indicates the presence of a bronchus leading to the lesion to be biopsied;\n3. Able to understand and willing to sign a written informed consent form. -\n\nExclusion Criteria:\n\n1. Those with contraindications to general anesthesia or bronchoscopy;\n2. Patients with uncorrectable coagulation disorders;\n3. Unable to discontinue therapeutic anticoagulants within an appropriate time interval before surgery;\n4. Patients with severe liver or kidney dysfunction, cardiovascular and cerebrovascular diseases, mental illnesses, etc.;\n5. Pregnant or lactating patients;\n6. Those without a clear histological or clinical diagnosis;\n7. Subjects deemed unsuitable by the investigator. -","ALL","18 Years","80 Years",{"count":19,"type":20},286,"ESTIMATED","OBSERVATIONAL","This study uses CelTouch to explore patients with lung lesions scheduled for lung biopsy. By comparing with preclinical CLE images and pathological images, CLE diagnostic criteria for benign and malignant lung lesions under the microscope will be established; the performance of CLE in diagnosing peripheral lung lesions will be validated through multicenter clinical research; and a CLE atlas for peripheral lung lesions will be constructed to establish a visual classification diagnostic system for peripheral lung lesions.\n\n(1) Comparative Study of In Vivo CLE Images and Pathological Images in the Diagnosis of Peripheral Lung Lesions\n\n1. Collect CLE images and histopathological sections of clearly diagnosed peripheral lung lesions.\n2. A diagnostic team composed of 1 bronchoscopy expert, 1 pathology expert, and 2 CLE experts will correlate in vivo and ex vivo CLE images of lung lesions with corresponding pathological images, analyze CLE image characteristics of benign and malignant lung lesions, and establish CLE diagnostic criteria for benign and malignant lung lesions.\n\n(2) Validation Study of the Diagnostic Performance of Confocal Laser Endomicroscopy in Peripheral Lung Lesions\n\n1. Multicenter screening of corresponding subjects according to inclusion and exclusion criteria, collection of corresponding videos and images during surgery, and recording of observed characteristic images based on pre-established diagnostic characteristics and criteria.\n2. The diagnostic team and sub-center representatives (5 in total) will perform offline interpretation of the collected images and videos, and evaluate the diagnostic performance of CLE in peripheral lung lesions using the accurate diagnostic results obtained from postoperative histopathology or 6-month clinical follow-up as the standard.\n3. Establishment of a CLE Atlas and Classification System for Lung Lesions\n\n(1) Collect large-scale in vivo and ex vivo CLE images and pathological images of clearly diagnosed lung lesions from multiple centers.\n\n(2) Select typical in vivo and ex vivo CLE images of lung lesions with the same pathological type and corresponding pathological images, and jointly describe the CLE image diagnostic characteristics by pathology experts and CLE experts to establish a CLE atlas for peripheral lung lesions.\n\n(3) Establish a visual classification system for the internal structure of peripheral lung lesions based on the special signs in CLE images of lung lesions.",[24],"Peripheral Pulmonary Lesion",[26],"peripheral pulmonary lesion","RECRUITING","2025-05-26",{"date":30,"type":31},"2025-06-04","ACTUAL",{"date":33,"type":20},"2025-05-31",{"date":35,"type":20},"2026-12-31",{"name":37,"class":38},"Guangzhou Medical University","OTHER",1,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":47,"enrollmentInfo":48,"targetDuration":4,"studyType":50,"phases":51,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":4},"100580102","a-real-world-case-study-evaluating-the-efficacy-and-safety-of-rbs-cryobiopsy-100580102","NCT06832930","A Real-World Case Study Evaluating the Efficacy and Safety of RBS Cryobiopsy","A Real-World Case Study Evaluating the Efficacy and Safety of Bronchial Navigation Localization Device-Assisted Cryobiopsy","Inclusion Criteria:\n\n* Inclusion Criteria:\n* Patients are eligible for inclusion if they meet all of the following criteria:\n\n  1. Age ≥18 years and ≤75 years, with no gender restrictions;\n  2. Presence of a peripheral lung lesion on chest CT\n  3. Patients voluntarily agree to undergo bronchoscopy and meet the requirements for the procedure;\n  4. patients are capable of understanding the purpose of the trial, demonstrate good compliance with the examinations and follow-up, voluntarily participate in the clinical trial, and sign an informed consent form.\n\nExclusion Criteria:\n\n* Patients who meet any of the following criteria will be excluded from this study:\n\n  1. Presence of contraindications for bronchoscopy, including: active massive hemoptysis; recent myocardial infarction or unstable angina; severe cardiac or pulmonary dysfunction; severe hypertension and arrhythmias; uncorrectable bleeding tendencies or severe coagulation disorders (such as platelet count \\\u003C60×10\\^9\u002FL), uremia; severe pulmonary artery hypertension; severe superior vena cava syndrome; intracranial hypertension; acute cerebrovascular events; aortic dissection or aneurysm; multiple bullae; extreme systemic exhaustion;\n  2. Female patients who are breastfeeding, pregnant, or planning pregnancy;\n  3. Patients with electromagnetic active implantable medical devices;\n  4. Subjects allergic to anesthetics; or with a history of multiple severe allergies, hereditary allergy history;\n  5. Those who have participated in or are currently participating in drug clinical trials within 3 months before screening, or have participated in other medical device clinical trials within 30 days;\n  6. Any other conditions deemed unsuitable for participation in this clinical trial by the investigator.\n\n     Exclusion Criteria:","75 Years",{"count":49,"type":20},200,"INTERVENTIONAL",[52],"NA","The goal of this clinical trial is tois to assess the effectiveness and safety of RBS (Robotic Bronchoscopy System)-assisted cryobiopsy in real-world clinical settings in adult patients (aged ≥18 years) with suspected pulmonary lesions requiring diagnostic bronchoscopic evaluation. The main questions it aims to answer are:\n\nDoes RBS-assisted cryobiopsy improve diagnostic yield compared to conventional non-RBS-guided cryobiopsy? Is RBS-assisted cryobiopsy associated with a lower incidence of procedure-related complications (e.g., bleeding, pneumothorax) compared to conventional methods? Researchers will compare the RBS group (patients undergoing RBS-assisted cryobiopsy) with the control group (patients undergoing cryobiopsy with conventional navigation techniques, such as ENB, VBN) to evaluate differences in diagnostic accuracy and safety outcomes.\n\nParticipants will:\n\nProvide informed consent for bronchoscopic cryobiopsy. Undergo pre-procedure imaging and clinical evaluation. Receive either RBS-assisted or conventional cryobiopsy based on clinical indication and operator discretion.\n\nBe monitored for immediate and delayed complications .",[24],"NOT_YET_RECRUITING","2025-02-12",{"date":58,"type":31},"2025-02-18",{"date":60,"type":20},"2025-02-15",{"date":62,"type":20},"2025-12-31",{"name":37,"class":38}]